Tag Archives: block-buster

Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease

Posted on October 16, 2013 by Barbara Arzymanow

Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant  Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading →

Posted in Business, Drugs, Innovation | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot: Think carefully about value-based drug pricing in the UK and let common sense prevail.

Posted on September 20, 2012 by Barbara Arzymanow

David Cameron and Jeremy Hunt share an important skill. They both have firsts from Oxford in Politics, Philosophy and Economics (PPE). I am not the greatest fan of this course because I would like to see more scientists, engineers and … Continue reading →

Posted in Business, competition, David Cameron, Department of Health, Drugs, Election, Jeremy Hunt, NHS, Patients, Pharma, Policy, Primary Care | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Guest Blogspot – The UK Needs More Biotechnology Companies

Posted on May 17, 2011 by Barbara Arzymanow

The success of US biotechnology companies contrasts sharply with the disappointment in other countries. British companies valued by stock markets at more than about US $ 4 billion go in the FTSE 100 index. There are no biotechnology companies big … Continue reading →

Posted in Business, Drugs, Emerging technologies, Finance, Genetics, Pharma, Policy, Research, Technology | Tagged , , , , , , , , , , , , , , , , , , , | 1 Comment